Ketamine and attentional bias to threat: dynamic causal modeling of magnetoencephalographic connectivity in treatment-resistant depression
Jessica R. Gilbert, Christina S. Galiano, Allison C. Nugent, Carlos A. Zarate
medRxiv Preprint Server February 22, 2021 preprint DOI: 10.1101/2021.02.22.21252247 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Double-blind, crossover, placebo-controlled study |
|---|---|
| Sample size | 34 |
| Population | Drug-free individuals with major depressive disorder and healthy volunteers |
| Intervention | Ketamine hydrochloride |
| Dose | 0.5 mg/kg |
| Duration | Single infusion; measurements taken prior to infusion and six to nine hours after drug and placebo infusions |
| Topics | Ketamine Depression Esketamine |
| Keywords | Depression treatment Brain activity |
| Key points | Ketamine administration led to faster GABA and NMDA transmission in the early visual cortex, faster NMDA transmission in the fusiform cortex, slower NMDA transmission in the amygdala, and reductions in depressive symptoms were associated with faster AMPA transmission and increases in gain control of spiny stellate cells in the early visual cortex. |
Abstract
The glutamatergic modulator ketamine rapidly reduces depressive symptoms in individuals with treatment-resistant major depressive disorder (MDD) and bipolar disorder. While its underlying mechanism of antidepressant action is not fully understood, modulating glutamatergically-mediated connectivity appears to be a critical component moderating antidepressant response. This double-blind, crossover, placebo-controlled study analyzed data from 19 drug-free individuals with MDD and 15 healthy volunteers who received a single intravenous infusion of ketamine hydrochloride (0.5 mg/kg) as well as an intravenous infusion of saline placebo. Magnetoencephalographic recordings were collected prior to the first infusion and six to nine hours after both drug and placebo infusions. During scanning, participants completed an attentional dot probe task that included emotional faces. Antidepressant response was measured across timepoints using the Montgomery-Asberg Depression Rating Scale (MADRS). Dynamic causal modeling (DCM) was used to measure changes in parameter estimates of connectivity via a biophysical model that included realistic local neuronal architecture and receptor channel signaling, modeling connectivity between the early visual cortex, fusiform cortex, amygdala, and inferior frontal gyrus. Clinically, ketamine administration significantly reduced depressive symptoms in MDD participants. Within the model, ketamine administration led to faster gamma aminobutyric acid (GABA) and N-methyl-D-aspartate (NMDA) transmission in the early visual cortex, faster NMDA transmission in the fusiform cortex, and slower NMDA transmission in the amygdala. Ketamine administration also led to direct and indirect changes in local inhibition in the early visual cortex and inferior frontal gyrus and to indirect increases in cortical excitability within the amygdala. Finally, reductions in depressive symptoms in MDD participants post-ketamine were associated with faster α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) transmission and increases in gain control of spiny stellate cells in the early visual cortex. These findings provide additional support for the GABA and NMDA inhibition and disinhibition hypotheses of depression and support the role of AMPA throughput in ketamine’s antidepressant effects.
Comparable studies
Other randomized controlled trials on ketamine for depression, most cited first.